Evidence map›Paper›PMID 35479316›Full record

ArticleFrontiers in pharmacology2022

A Triple High Throughput Screening for Extracellular Vesicle Inducing Agents With Immunostimulatory Activity.

Nikunj M Shukla, Fumi Sato-Kaneko, Shiyin Yao, Minya Pu, Michael Chan, Fitzgerald S Lao, Yukiya Sako, Tetsuya Saito, Karen Messer, Tomoko Hayashi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Nikunj M ShuklaMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Fumi Sato-KanekoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Shiyin YaoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Minya PuThe Herbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, CA, United States.
Michael ChanMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Fitzgerald S LaoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Yukiya SakoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Tetsuya SaitoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Karen MesserThe Herbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, CA, United States.
Tomoko HayashiMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Howard B CottamMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Maripat CorrDepartment of Medicine, University of California San Diego, La Jolla, CA, United States.
Dennis A CarsonMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
University of California, San Diego · USHuman Longevity (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) play an important role in intercellular communication and regulation of cells, especially in the immune system where EVs can participate in antigen presentation and may have adjuvant effects. We aimed to identify small molecule compounds that can increase EV release and thereby enhance the immunogenicity of vaccines. We utilized a THP-1 reporter cell line engineered to release EV-associated tetraspanin (CD63)-Turbo-luciferase to quantitatively measure EVs released in culture supernatants as a readout of a high throughput screen (HTS) of 27,895 compounds. In parallel, the cytotoxicity of the compounds was evaluated by PrestoBlue dye assay. For screening immunostimulatory potency, we performed two additional independent HTS on the same compound library using NF-κB and interferon-stimulated response element THP-1 reporter cell lines. Hit compounds were then identified in each of the 3 HTS's, using a "Top X″ and a Gaussian Mixture Model approach to rule out false positive compounds and to increase the sensitivity of the hit selection. Thus, 644 compounds were selected as hits which were further evaluated for induction of IL-12 in murine bone-marrow derived dendritic cells (mBMDCs) and for effects of cell viability. The resulting 130 hits were then assessed from a medicinal chemistry perspective to remove compounds with functional group liabilities. Finally, 80 compounds were evaluated as vaccine adjuvants

Indexed as

adjuvantcompoundsexosome (vesicle)extracellularHTSimmuneNFkBreporter cells

Identifiers

PMID35479316
PMCPMC9035538
OpenAlexW4223516962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.